These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

776 related items for PubMed ID: 29084746

  • 1. Use of Calgary and Microfluidic BioFlux Systems To Test the Activity of Fosfomycin and Tobramycin Alone and in Combination against Cystic Fibrosis Pseudomonas aeruginosa Biofilms.
    Díez-Aguilar M, Morosini MI, Köksal E, Oliver A, Ekkelenkamp M, Cantón R.
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084746
    [Abstract] [Full Text] [Related]

  • 2. Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions.
    McCaughey G, McKevitt M, Elborn JS, Tunney MM.
    J Cyst Fibros; 2012 May; 11(3):163-72. PubMed ID: 22138067
    [Abstract] [Full Text] [Related]

  • 3. Anti-biofilm activity of murepavadin against cystic fibrosis Pseudomonas aeruginosa isolates.
    Díez-Aguilar M, Ekkelenkamp M, Morosini MI, Huertas N, Del Campo R, Zamora J, Fluit AC, Tunney MM, Obrecht D, Bernardini F, Cantón R.
    J Antimicrob Chemother; 2021 Sep 15; 76(10):2578-2585. PubMed ID: 34283223
    [Abstract] [Full Text] [Related]

  • 4. Antimicrobial activity of tobramycin against respiratory cystic fibrosis Pseudomonas aeruginosa isolates from Bulgaria.
    Strateva T, Petrova G, Mitov I.
    J Chemother; 2010 Dec 15; 22(6):378-83. PubMed ID: 21303744
    [Abstract] [Full Text] [Related]

  • 5. In vitro activity of antibiotic combinations against Pseudomonas aeruginosa biofilm and planktonic cultures.
    Tré-Hardy M, Vanderbist F, Traore H, Devleeschouwer MJ.
    Int J Antimicrob Agents; 2008 Apr 15; 31(4):329-36. PubMed ID: 18280117
    [Abstract] [Full Text] [Related]

  • 6. Eradication of Pseudomonas aeruginosa biofilms on cultured airway cells by a fosfomycin/tobramycin antibiotic combination.
    Anderson GG, Kenney TF, Macleod DL, Henig NR, O'Toole GA.
    Pathog Dis; 2013 Feb 15; 67(1):39-45. PubMed ID: 23620118
    [Abstract] [Full Text] [Related]

  • 7. Resistance development of cystic fibrosis respiratory pathogens when exposed to fosfomycin and tobramycin alone and in combination under aerobic and anaerobic conditions.
    McCaughey G, Diamond P, Elborn JS, McKevitt M, Tunney MM.
    PLoS One; 2013 Feb 15; 8(7):e69763. PubMed ID: 23936095
    [Abstract] [Full Text] [Related]

  • 8. Synergistic effects of aminoglycosides and fosfomycin on Pseudomonas aeruginosa in vitro and biofilm infections in a rat model.
    Cai Y, Fan Y, Wang R, An MM, Liang BB.
    J Antimicrob Chemother; 2009 Sep 15; 64(3):563-6. PubMed ID: 19561148
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of long-term co-administration of tobramycin and clarithromycin in a mature biofilm model of cystic fibrosis clinical isolates of Pseudomonas aeruginosa.
    Tré-Hardy M, Traore H, El Manssouri N, Vanderbist F, Vaneechoutte M, Devleeschouwer MJ.
    Int J Antimicrob Agents; 2009 Oct 15; 34(4):370-4. PubMed ID: 19505804
    [Abstract] [Full Text] [Related]

  • 10. Synergistic effects of inhaled aztreonam plus tobramycin on hypermutable cystic fibrosis Pseudomonas aeruginosa isolates in a dynamic biofilm model evaluated by mechanism-based modelling and whole genome sequencing.
    Breen SKJ, Harper M, López-Causapé C, Rogers KE, Tait JR, Smallman TR, Lang Y, Lee WL, Zhou J, Zhang Y, Bulitta JB, Nation RL, Oliver A, Boyce JD, Landersdorfer CB.
    Int J Antimicrob Agents; 2024 Jun 15; 63(6):107161. PubMed ID: 38561094
    [Abstract] [Full Text] [Related]

  • 11. PEGylation of Tobramycin Improves Mucus Penetration and Antimicrobial Activity against Pseudomonas aeruginosa Biofilms in Vitro.
    Bahamondez-Canas TF, Zhang H, Tewes F, Leal J, Smyth HDC.
    Mol Pharm; 2018 Apr 02; 15(4):1643-1652. PubMed ID: 29514003
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of the E test for the assessment of synergy of antibiotic combinations against multiresistant Pseudomonas aeruginosa isolates from cystic fibrosis patients.
    Balke B, Hogardt M, Schmoldt S, Hoy L, Weissbrodt H, Häussler S.
    Eur J Clin Microbiol Infect Dis; 2006 Jan 02; 25(1):25-30. PubMed ID: 16402226
    [Abstract] [Full Text] [Related]

  • 13. Antimicrobial Activity of Fosfomycin-Tobramycin Combination against Pseudomonas aeruginosa Isolates Assessed by Time-Kill Assays and Mutant Prevention Concentrations.
    Díez-Aguilar M, Morosini MI, Tedim AP, Rodríguez I, Aktaş Z, Cantón R.
    Antimicrob Agents Chemother; 2015 Oct 02; 59(10):6039-45. PubMed ID: 26195514
    [Abstract] [Full Text] [Related]

  • 14. Fosfomycin and tobramycin in combination downregulate nitrate reductase genes narG and narH, resulting in increased activity against Pseudomonas aeruginosa under anaerobic conditions.
    McCaughey G, Gilpin DF, Schneiders T, Hoffman LR, McKevitt M, Elborn JS, Tunney MM.
    Antimicrob Agents Chemother; 2013 Nov 02; 57(11):5406-14. PubMed ID: 23959314
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Synergistic Meropenem-Tobramycin Combination Dosage Regimens against Clinical Hypermutable Pseudomonas aeruginosa at Simulated Epithelial Lining Fluid Concentrations in a Dynamic Biofilm Model.
    Bilal H, Bergen PJ, Kim TH, Chung SE, Peleg AY, Oliver A, Nation RL, Landersdorfer CB.
    Antimicrob Agents Chemother; 2019 Nov 02; 63(11):. PubMed ID: 31427301
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.